MiR-196b regulates gastric cancer cell proliferation and invasion via PI3K/AKT/mTOR signaling pathway

Oncology Letters

Volumn 11, Issue 3, 2016, Pages 1745-1749

  Li, Na ^a   Wang, Weiqiang ^b   Xu, Bin ^a   Gong, Hongyun ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b The 281st Hospital of People's Liberation Army   (China)

Author keywords

AKT; Gastric cancer; Invasion; miR 196b; MTOR; PI3K; Proliferation

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MICRORNA; MICRORNA 196B; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CYCLE ASSAY; CELL INVASION; CELL INVASION ASSAY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ESCHERICHIA COLI; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; G1 PHASE CELL CYCLE CHECKPOINT; HEK293 CELL LINE; LENTIVIRINAE; MOUSE; MTT ASSAY; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STOMACH CANCER; UPREGULATION; WESTERN BLOTTING;

EID: 84958078587     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2016.4141     Document Type: Article

References (26)

1. Wu R, Li F, Zhu J, Tang R, Qi Q, Zhou X, Li R, Wang W, Hua D and Chen W: A functional variant at mir-132-3p, mir-212-3p and mir-361-5p binding site in cd80 gene alters susceptibility to gastric cancer in a Chinese Han population. Med Oncol 31: 60, 2014.
2. Xu YJ and Fan Y: Mir-215/192 participates in gastric cancer progression. Clin Transl Oncol 17: 34-40, 2015.
3. Shen ZY, Zhang ZZ, Liu H, Zhao EH and Cao H: Mir-375 inhibits the proliferation of gastric cancer cells by repressing ERBB2 expression. Exp Ther Med 7: 1757-1761, 2014.
4. Li H, Xie S, Liu M, Chen Z, Liu X, Wang L, Li D and Zhou Y: The clinical significance of downregulation of mir-124-3p, mir-146a-5p, mir-155-5p and mir-335-5p in gastric cancer tumorigenesis. Int J Oncol 45: 197-208, 2014.
5. Xia J, Guo X, Yan J and Deng K: The role of mir-148a in gastric cancer. J Cancer Res Clin Oncol 140: 1451-1456, 2014.
6. Zheng Y, Li S, Ding Y, Wang Q, Luo H, Shi Q, Hao Z, Xiao G and Tong S: The role of mir-18a in gastric cancer angiogenesis. Hepatogastroenterology 60: 1809-1813, 2013.
7. Duan Y, Hu L, Liu B, Yu B, Li J, Yan M, Yu Y, Li C, Su L, Zhu Z, et al: Tumor suppressor miR-24 restrains gastric cancer progression by downregulating regIV. Mol Cancer 13: 127, 2014.
8. He XJ, Ma YY, Yu S, Jiang XT, Lu YD, Tao L, Wang HP, Hu ZM and Tao HQ: Up-regulated miR-199a-5p in gastric cancer functions as an oncogene and targets klotho. BMC Cancer 14: 218, 2014.
9. Hornstein E, Mansfield JH, Yekta S, Hu JK, Harfe BD, McManus MT, Baskerville S, Bartel DP and Tabin CJ: The microRNA-miR-196 acts upstream of hoxb8 and shh in limb development. Nature 438: 671-674, 2005.
10. Sehm T, Sachse C, Frenzel C and Echeverri K: miR-196 is an essential early-stage regulator of tail regeneration, upstream of key spinal cord patterning events. Dev Biol 334: 468-480, 2009.
11. Kawasaki H and Taira K: MicroRNA-196 inhibits HOXB8 expression in myeloid differentiation of HL60 cells. Nucleic Acids Symp Ser (Oxf) 48: 211-212, 2004.
12. Brest P, Lapaquette P, Souidi M, Lebrigand K, Cesaro A, Vouret-Craviari V, Mari B, Barbry P, Mosnier JF, Hébuterne X, et al: A synonymous variant in IRGM alters a binding site for miR-196 and causes deregulation of IRGM-dependent xenophagy in crohn's disease. Nat Genet 43: 242-245, 2011.
13. Hezova R, Kovarikova A, Bienertova-Vasku J, Sachlova M, Redova M, Vasku A, Svoboda M, Radova L, Kiss I, Vyzula R and Slaby O: Evaluation of SNPs in miR-196-a2, miR-27a and miR-146a as risk factors of colorectal cancer. World J Gastroenterol 18: 2827-2831, 2012.
14. Hou W, Tian Q, Zheng J and Bonkovsky HL: MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins. Hepatology 51: 1494-1504, 2010.
15. Chen C, Zhang Y, Zhang L, Weakley SM and Yao Q: MicroRNA-196: Critical roles and clinical applications in development and cancer. J Cell Mol Med 15: 14-23, 2011.
16. Popovic R, Riesbeck LE, Velu CS, Chaubey A, Zhang J, Achille NJ, Erfurth FE, Eaton K, Lu J, Grimes HL, et al: Regulation of mir-196b by MLL and its overexpression by MLL fusions contributes to immortalization. Blood 113: 3314-3322, 2009.
17. Schotte D, Lange-Turenhout EA, Stumpel DJ, Stam RW, Buijs-Gladdines JG, Meijerink JP, Pieters R and Den Boer ML: Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia. Haematologica 95: 1675-1682, 2010.
18. Li Z, Huang H, Chen P, He M, Li Y, Arnovitz S, Jiang X, He C, Hyjek E, Zhang J, et al: miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia. Nat Commun 3: 688, 2012.
19. Abbud-Antaki RA, Marhefka JN, DeLuca AL and Zuromskis MP: The cancer biochip system: a functional genomic assay for anchorage-independent three-dimensional breast cancer cell growth. Horm Cancer 3: 261-270, 2012.
20. Guadamillas MC, Cerezo A and Del Pozo MA: Overcoming anoikis-pathways to anchorage-independent growth in cancer. J Cell Sci 124: 3189-3197, 2011.
21. Okabe H, Ishimoto T, Mima K, Nakagawa S, Hayashi H, Kuroki H, Imai K, Nitta H, Saito S, Hashimoto D, et al: CD44s signals the acquisition of the mesenchymal phenotype required for anchorage-independent cell survival in hepatocellular carcinoma. Br J Cancer 110: 958-966, 2014.
22. Marshall J: Transwell(®) invasion assays. Methods Mol Biol 769: 97-110, 2011.
23. Tapia O, Riquelme I, Leal P, Sandoval A, Aedo S, Weber H, Letelier P, Bellolio E, Villaseca M, Garcia P and Roa JC: The Pi3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance. Virchows Arch 465: 25-33, 2014.
24. Sukawa Y, Yamamoto H, Nosho K, Ito M, Igarashi H, Naito T, Mitsuhashi K, Matsunaga Y, Takahashi T, Mikami M, et al: HER2 expression and Pi3K-Akt pathway alterations in gastric cancer. Digestion 89: 12-17, 2014.
25. Xie X, Tang B, Zhou J, Gao Q and Zhang P: Inhibition of the Pi3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine. Oncol Rep 30: 773-782, 2013.
26. Ye B, Jiang LL, Xu HT, Zhou DW and Li ZS: Expression of Pi3K/AKT pathway in gastric cancer and its blockade suppresses tumor growth and metastasis. Int J Immunopathol Pharmacol 25: 627-636, 2012.